MET Gene High Copy Number (Amplification/Polysomy) Identified in Melanoma for Potential Targeted Therapy
Authors:
- 7 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 157 (4) , 502-505
Abstract
Aberrant expression of the mesenchymal epithelial transition factor (MET) gene has been observed in several malignancies, and drugs targeting the MET gene have been implicated in clinical trials with promising results. Hence, MET is a potentially targetable oncogenic driver. We explored the frequency of MET gene high copy number in melanomas and carcinomas. The study group included 135 patients. Tissue microarrays were constructed with 19 melanomas and 116 carcinomas diagnosed from 2010 to 2012. We screened MET gene copy number by fluorescence in situ hybridization analysis using probes for MET gene and CEP7 as control. We found MET gene amplification in 2 (11%) of 19 melanoma cases, whereas 5 (26%) of 19 melanoma cases showed polysomy. For carcinomas, there was no MET gene amplification identified. However, 8 (7%) of 116 cases showed polysomy. In our study, MET gene amplification was identified in 11% of melanomas and is relatively concordant with few reported studies. However, about 26% of the additional melanoma cases showed MET gene polysomy, which has not been reported as per our knowledge. If these results are validated with further orthogonal studies, more of the melanoma cases could potentially benefit from targeted therapy with MET tyrosine kinase inhibitors.Keywords
This publication has 18 references indexed in Scilit:
- Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancerOncotarget, 2015
- Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitorsOncoTargets and Therapy, 2014
- The Current State of Molecularly Targeted Drugs Targeting HGF/MetJapanese Journal of Clinical Oncology, 2013
- The emerging role of MET/HGF inhibitors in oncologyCancer Treatment Reviews, 2013
- Targeting the HGF/c-MET Pathway in Hepatocellular CarcinomaClinical Cancer Research, 2013
- Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2012
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET AmplificationJournal of Thoracic Oncology, 2011
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerCancer Science, 2008
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006